Ozempic vs Wegovy: Same Molecule, Different Program — What Actually Differs
Same molecule (semaglutide), same manufacturer (Novo Nordisk), different brand names with different indications. Here's what actually distinguishes Ozempic from Wegovy.
The Real Differences
| Feature | Ozempic | Wegovy |
|---|---|---|
| Approved indication | Type 2 diabetes | Chronic weight management |
| FDA-approved dose range | Up to 2 mg weekly | Up to 2.4 mg weekly |
| Insurance coverage patterns | Broadly covered for T2D | More restricted for weight |
| Cash-pay pricing | Varies (retail cash) | NovoCare tiers |
| Off-label weight-loss use | Historically common | On-label |
Sesame Care
Marketplace for brand-name FDA-approved GLP-1 only.
- Brand-name only
- Direct consult marketplace
- Cash-pay clarity
Found Health
Brand-name GLP-1 access with coaching layer.
- Brand-name focus
- Coaching + accountability
- Insurance-coordinated
Why the Two Brands Exist
The two brands reflect regulatory structure. FDA approvals are for specific indications; a drug approved for type 2 diabetes has to go through a separate approval process to be marketed for weight management, and typically at different doses. Novo pursued Ozempic (T2D) first and Wegovy (weight management) as a separate development track with its own trials, doses, and label.
The molecule itself — semaglutide — is identical in both products. What differs is the branded packaging, the dosing device (pens), the FDA-approved indication, and how insurance covers it.
The Off-Label Prescribing Pattern
Prescribers historically wrote Ozempic off-label for weight loss when Wegovy wasn't available or covered. This was legal but insurance-dependent — some plans covered Ozempic broadly, others required diabetes diagnosis. Post-Wegovy approval and post-shortage, off-label Ozempic prescribing for weight loss has diminished as Wegovy access has improved and payers have tightened Ozempic prior authorization for non-diabetes use.
Oak Weight Loss
Telehealth program with compounded GLP-1 access.
- Compounded GLP-1
- Standard intake
- Membership pricing
For Patients Currently on Ozempic for Weight Loss
If you're on Ozempic off-label for weight loss, discuss with your prescriber whether transitioning to Wegovy makes sense. Wegovy's higher approved dose (2.4 mg vs 2 mg) may provide additional weight loss. Coverage decisions may work better with the on-label prescription. Practical continuity should be smooth given the same underlying molecule.
Embody
Injectable semaglutide only — lead compounded option.
- Injectable semaglutide focus
- Standard titration
- Direct pharmacy shipping
Wellorithm
Compounded GLP-1 with dose-tier pricing.
- Sema and tirz options
- Tier pricing by dose
- Verify at intake
The Compounded Consideration
Compounded semaglutide isn't Ozempic and isn't Wegovy — it's compounded semaglutide, prepared for individual patients under 503A rules. It's the same molecule but not the same product. For patients who want the molecule at lower cost and don't need the FDA-approved product, compounded pathways offer that option (with the trade-offs discussed in other articles on this site).
MadeMed
Independent compounder — sema, tirz, and oral formats.
- Compounded sema/tirz
- Oral tirz $167-229
- Direct pharmacy fulfillment
Telos Rx
Compounded tirzepatide via direct pharmacy.
- Compounded tirzepatide
- Direct-link intake
- Verify pricing
Where to Start
Embody
Injectable semaglutide only — lead compounded option.
- Injectable semaglutide focus
- Standard titration
- Direct pharmacy shipping
Wellorithm
Compounded GLP-1 with dose-tier pricing.
- Sema and tirz options
- Tier pricing by dose
- Verify at intake
MadeMed
Independent compounder — sema, tirz, and oral formats.
- Compounded sema/tirz
- Oral tirz $167-229
- Direct pharmacy fulfillment